Abstract: This disclosure describes microfluidic tissue biopsy and immune response drug evaluation devices and systems. A microfluidic device can include an inlet channel having a first end configured to receive a fluid sample optionally containing a tissue sample. The microfluidic device can also include a tissue trapping region at the second end of the inlet channel downstream from the first end. The tissue trapping region can include one or more tissue traps configured to catch a tissue sample flowing through the inlet channel such that the fluid sample contacts the tissue trap. The microfluidic device can also include one or more channels providing an outlet.

Abstract: A controlled release system includes a polymeric support, wherein the polymeric support is biodegradable; a polymeric matrix, wherein the polymeric matrix includes polyhydroalkanoate; and encapsulated gases or volatiles; and a controlled release system includes a polymeric support; a polymeric matrix, wherein the polymeric matrix includes (poly-3-hydroxybutyrate-co-3-hydroxyvalerate) and poly (?-caprolactone); and encapsulated gases or volatiles.

Abstract: The cell phone case with integrated hooks is configured for use with a personal data device. The cell phone case with integrated hooks is a housing that contains the personal data device. The cell phone case with integrated hooks comprises a housing, a plurality of fasteners, and a removable pad. The plurality of fasteners are retractably installed within the housing. Each of the plurality of fasteners attach the housing to a vertical surface such that the personal data device may be hung from the vertical surface thereby allowing the personal data device to be used in a hands free manner. The removable pad provides an anchor point for use by the plurality of fasteners when hanging the personal data device.

Abstract: The invention relates to a novel pharmaceutical formulation comprising polymer nanoparticles of the biodegradable and biocompatible polymer poly(lactic-glycolic) acid (PLGA), loaded with the drug pentoxifylline, the method for the synthesis of the PLGA nanoparticles loaded with pentoxifylline, and to the use thereof in the effective treatment for the relief of chronic pain and for the prevention of chronic pain via the administration of a single dose.

Abstract: The present disclosure introduces new multi-functional vibrating devices, methods of using the devices, and methods of manufacturing the devices. A multi-functional vibrating device can include one or more actuators, each paired with an amplifier capable of converting small lateral vibration into large vertical vibration. The present disclosure also involves interactive information acquisition technologies and assistive technologies, particularly devices, methods, and systems for tactile information transfer and acquisition. Some embodiments incorporate multi-functional vibrational devices, methods, and systems to achieve unique structural and operational characteristics—such as high-resolution, robustness, versatility, compactness, and/or rapid refresh rates—for communicating information. Some embodiments can convert information from a format that is less convenient and/or accessible in some cases (e.g., visual or audio) to an intuitive and/or private format (e.g., tactile patterns and motions).

Abstract: It is described a 3D monocular tracking system, being robust, having low cost, easy to install and use, useful for the upper limbs rehabilitation in a patient in need thereof, as well as a home self-directed therapy method for patients having upper limbs' movement disability. The system comprising a) a handle or gripper; b) a computational vision system comprising a video camera; c) software comprising a set of games; d) a processor; and, e) a display apparatus.

Abstract: The present invention provides an alkaloid compound that is an inhibitor of mycotoxin biosynthesis. The alkaloid is an alkenyl piperidine amide wherein the alkenyl is a C18 alkenyl with one or more double bonds. The alkaloid inhibits transcription of the fungus genes nor-1, tri5, and ipnA. The present invention further provides a method for identifying compounds, which inhibit biosynthesis of aflatoxin in Aspergillus spp. and deoxynivalenol in Gibberella spp. without inhibiting growth of the fungus in vitro.

Abstract: The present invention provides an alkaloid compound that is an inhibitor of mycotoxin biosynthesis. The alkaloid is an alkenyl piperidine amide wherein the alkenyl is a C18 alkenyl with one or more double bonds. The alkaloid inhibits transcription of the fungus genes nor-1, tri5, and ipnA. The present invention further provides a method for identifying compounds, which inhibit biosynthesis of aflatoxin in Aspergillus spp. and deoxynivalenol in Gibberella spp. without inhibiting growth of the fungus in vitro.

Abstract: The present invention provides an alkaloid compound that is an inhibitor of mycotoxin biosynthesis. The alkaloid is an alkenyl piperidine amide wherein the alkenyl is a C18 alkenyl with one or more double bonds. The alkaloid inhibits transcription of the fungus genes nor-1, tri5, and ipnA. The present invention further provides a method for identifying compounds, which inhibit biosynthesis of aflatoxin in Aspergillus spp. and deoxynivalenol in Gibberella spp. without inhibiting growth of the fungus in vitro.